Financial Data and Key Metrics Changes - Omada Health achieved 53% revenue growth for the full year 2025, reaching $260 million, with Q4 revenue growing 58% year-over-year to $76 million [4][30] - The total number of members increased to 886,000, a 55% increase compared to 2024, with 55,000 net new members added in Q4 alone [4][17] - GAAP net income was $5 million in Q4, marking the first quarter of profitability, and a full-year GAAP net loss of $13 million, an improvement from a loss of $47 million in 2024 [30][35] - Adjusted EBITDA for the full year was $6 million, with a margin of 2%, compared to a loss of $29 million in 2024 [35][36] Business Line Data and Key Metrics Changes - The GLP-1 Care Track program saw significant adoption, with over 150,000 members supported on GLP-1s, contributing to the overall growth in the cardiometabolic suite [10][19] - Revenue from the weight health program grew more than 50%, while revenue from diabetes and hypertension programs grew at rates of 45% or more year-over-year [27][68] Market Data and Key Metrics Changes - Estimated covered lives grew by more than 5 million, ending the year with over 25 million eligible lives [18] - The total addressable market for Omada is estimated at over $138 billion, with current penetration below 10% [19] Company Strategy and Development Direction - Omada's strategy focuses on innovation, effective programs, and a multi-condition platform to address cardiometabolic health [20][25] - The company plans to expand capabilities in GLP-1 prescribing, cholesterol management, and flexible care options to enhance its service offerings [12][24] - Investments in AI are aimed at improving member support and operational efficiency, with a focus on leveraging unique data sets for personalized care [14][65] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a clear plan for growth, emphasizing the importance of addressing chronic care solutions [4][10] - The healthcare system's inability to scale effectively without a different care model was highlighted, with Omada positioned to fill this gap [8][9] - The company anticipates continued strong growth driven by the demand for multi-condition care and effective enrollment strategies [30][38] Other Important Information - Omada's gross margins expanded significantly, with Q4 GAAP gross margin reaching 71%, up from 67% in the prior year [31] - The company generated positive operating cash flow for the full year and ended 2025 with $222 million in cash and cash equivalents [37] Q&A Session Summary Question: Can you clarify the assumptions behind the 2026 guidance? - Management confirmed that the guidance is based on existing business contributions without assuming significant improvements in enrollment or engagement metrics [42][44] Question: What are the mechanics of the new GLP-1 Flex Care program? - The GLP-1 Flex Care program is designed to support employers who do not currently cover GLP-1s, providing a structured model for clinical evaluation and prescribing while allowing employees to purchase medications out-of-pocket [54][56] Question: How is Omada leveraging AI in its operations? - Omada is utilizing AI for coding assistance, member support, and enhancing the overall member experience, which is expected to improve margins [64][65] Question: What traction is being seen in the hypertension and diabetes programs? - Growth in diabetes and hypertension programs is strong, with both seeing year-over-year growth rates of 45% or more, reflecting the integrated approach to cardiometabolic care [66][68]

Financial Data and Key Metrics Changes - Omada Health achieved 53% revenue growth for the full year 2025, reaching $260 million, with Q4 revenue growing 58% year-over-year to $76 million [4][30] - The total member count increased to 886,000, a 55% increase compared to 2024, with 55,000 net new members added in Q4 alone [4][17] - GAAP net income was positive for the first time in Q4 at $5 million, improving from a net loss of $8 million in Q4 2024 [30][35] - Adjusted EBITDA for the full year was $6 million, a significant improvement from a loss of $29 million in 2024 [30][35] Business Line Data and Key Metrics Changes - Revenue from the weight health program grew over 50%, while revenue from diabetes and hypertension programs grew at rates of 45% or more year-over-year [27][68] - The GLP-1 Care Track saw significant adoption, with over 150,000 members supported on GLP-1s, adding more than 100,000 in 2025 [10][19] - The introduction of the GLP-1 prescribing capability and the new GLP-1 Flexcare option are expected to enhance the company's service offerings and revenue potential [11][22] Market Data and Key Metrics Changes - Estimated covered lives grew by more than 5 million, ending the year with over 25 million eligible lives [18] - The total addressable market for Omada's services is estimated at over $138 billion, with current penetration below 10% [19] - Government initiatives, such as the PREVENT DIABETES Act, are expected to enhance the recognition of virtual care solutions, expanding access to quality care [19][20] Company Strategy and Development Direction - Omada's strategy focuses on innovation, effective programs, and a multi-condition platform to address cardiometabolic health [20][25] - The company aims to balance growth and profitability, targeting long-term adjusted EBITDA margins of over 20% [16][34] - Investments in AI and technology are expected to enhance member experience and operational efficiency [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a clear plan for growth, driven by market demand for chronic care solutions [4][5] - The company anticipates continued strong performance, with 2026 revenue guidance in the range of $312 million to $322 million, reflecting 22% growth over 2025 [37][38] - Management highlighted the importance of leveraging unique data sets and AI to improve care personalization and operational efficiency [65] Other Important Information - Omada's GAAP gross margin improved to 71% in Q4, up from 67% in the prior year, indicating strong operational leverage [31][32] - The company ended 2025 with $222 million in cash and cash equivalents, having generated positive operating cash flow for the year [37] Q&A Session Summary Question: Can you clarify the assumptions behind the 2026 guidance? - Management confirmed that the guidance is based on existing business performance without significant contributions from new opportunities, indicating a conservative approach [42][46] Question: How is the GLP-1 FlexCare program structured? - The GLP-1 FlexCare program provides a structured model for employers to support employees with clinical evaluation and prescribing, while allowing employees to purchase medications out-of-pocket [56] Question: What are the growth prospects for diabetes and hypertension programs? - Management noted that growth in diabetes and hypertension programs is strong, with both growing at rates similar to overall revenue growth, reflecting the integrated cardiometabolic approach [66][68]

Financial Data and Key Metrics Changes - Omada Health achieved a 53% revenue growth for the full year 2025, reaching $260 million, with Q4 revenue growing 58% year-over-year to $76 million [4][29] - The total number of members increased to 886,000, a 55% increase compared to 2024, with 55,000 net new members added in Q4 alone [4][17] - The company achieved its first quarter of positive GAAP net income in Q4, reporting $5 million, and delivered positive full-year adjusted EBITDA of $6 million [4][34] Business Line Data and Key Metrics Changes - Revenue from the weight health program grew more than 50%, while revenue from diabetes and hypertension programs grew at rates of 45% or more year-over-year [27][69] - The GLP-1 Care Track saw significant adoption, with over 150,000 members supported on GLP-1s, and members on average achieved greater weight loss compared to published real-world evidence [10][11] Market Data and Key Metrics Changes - Estimated covered lives grew by more than 5 million, ending the year with over 25 million estimated eligible lives [18] - The company noted strong performance across multiple channels, including a successful launch of a large new channel partner [17] Company Strategy and Development Direction - Omada Health is focused on expanding its multi-condition platform, which includes weight health, diabetes, hypertension, and cholesterol management, to provide integrated care solutions [8][24] - The company aims to leverage AI to enhance member support and operational efficiency, embedding AI throughout its services [12][66] - The strategy includes maintaining a balance between growth and profitability, targeting long-term adjusted EBITDA margins of over 20% [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with momentum and a clear plan, highlighting the strong market demand for chronic care solutions and AI-driven innovation [4][5] - The company anticipates 2026 revenue in the range of $312 million to $322 million, reflecting a 22% growth over 2025 [36][37] Other Important Information - Omada Health's GAAP gross margin improved to 71% in Q4, up from 67% in the prior year, and adjusted gross margin reached an all-time high of 73% [30][31] - The company ended 2025 with $222 million in cash and cash equivalents, having generated positive operating cash flow for the year [36] Q&A Session Summary Question: Can you clarify the assumptions behind the 2026 guidance? - Management confirmed that the guidance is based on existing business contributions and does not include new opportunities like GLP-1 prescribing or FlexCare, which could provide upside [42][46] Question: How did January and February track in terms of conversions? - Management reported strong performance in closing additional eligible covered lives and improved enrollment rates, indicating positive trends early in 2026 [48] Question: What is the impact of the new GLP-1 FlexCare program on economics? - The FlexCare program allows employers to support employees with structured models for GLP-1 access, which includes compensation for Omada for facilitating connections [53][56] Question: How is Omada leveraging AI to improve operations? - Omada is utilizing AI for member support and operational efficiencies, with a focus on unique data sets that enhance personalized care [65][66] Question: What traction is being seen in hypertension and diabetes programs? - Management noted strong growth in both diabetes and hypertension programs, reflecting the integrated cardiometabolic care approach [68][69]

Core Insights - Omada Health, Inc. reported a significant revenue increase of 58% in the fourth quarter and 53% for the full year 2025, reaching $76 million and $260 million respectively [1][7] - The company achieved positive net income of $5 million in the fourth quarter, a notable improvement from a net loss of $8 million in the same quarter of 2024, and narrowed its full-year net loss to $13 million from $47 million in 2024 [8][7] - Omada delivered positive adjusted EBITDA of $8 million in the fourth quarter and $6 million for the full year, compared to adjusted EBITDA losses in the previous year [14][8] Member Growth - Total membership reached 886,000 by year-end 2025, reflecting a 55% year-over-year growth [3] Revenue and Financial Performance - Revenue for the fourth quarter was $76 million, up 58% year-over-year, while the full-year revenue was $260 million, up 53% compared to 2024 [7] - Gross margin improved to 71% in the fourth quarter from 67% in Q4 2024, and for the full year, it was 66%, up from 61% in 2024 [8] - Non-GAAP gross margin for the fourth quarter was 73%, up from 69% in Q4 2024, and for the full year, it was 68%, compared to 63% in 2024 [8] Program Innovations and Offerings - The company introduced GLP-1 Flex Care, a new option for employers to connect eligible employees with clinical evaluation and ongoing medical oversight for GLP-1s, enhancing access and affordability [7][5] - Omada launched AI-powered tools, OmadaSpark and Meal Map, to support members with wellness education alongside human coaches [7][5] - In February 2026, Omada announced a new program, Omada for Cholesterol, to address prevalent conditions often co-existing with diabetes and obesity, expanding its cardiometabolic care capabilities [7][5] Financial Outlook - For the year ending December 31, 2026, Omada expects revenue in the range of $312 million to $322 million, representing a midpoint growth of 22% compared to 2025 [15] - Adjusted EBITDA is projected to be between $7 million and $15 million [15]

Building a Between-Visit Provider As of March 5, 2026 Christine Real Omada Member Important Notice and Disclaimers Disclaimers Our Mission Bend the curve 3 3 This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "tar ...

Omada Health FY Conference Summary Company Overview - **Company**: Omada Health (NasdaqGS:OMDA) - **Industry**: Health Care Services and Technology - **Recent Event**: IPO over the summer of 2025, indicating strong market interest and performance [2][3][5] Core Business Model - Omada Health operates as a "between-visit care provider," focusing on chronic disease management [5][9] - The business model involves charging self-insured employers, fully insured plans, and integrated systems a monthly membership fee for comprehensive services [9][10] - The mission is to improve health outcomes and reduce costs through persistent longitudinal care [5][9] New Service Offerings - Introduction of the **GLP-1 Care Track** aimed at supporting weight loss for members on therapy, showing a 28% increase in weight loss outcomes [18][19] - The service is designed to help members optimize medication use and reduce waste, addressing employer concerns about medication costs and effectiveness [19][20] Financial Insights - The monthly fee structure will increase if clients opt for the prescribing capability, which is expected to be accretive to revenue and margins [24][25] - Long-term targets include achieving over 20% operating margins while maintaining growth [31] Market Dynamics - Anticipated that the GLP-1 prescribing care track will contribute to the P&L primarily in 2027, with some potential deployments in 2026 [37] - The selling season for 2026 is characterized by strong interest from employers, with a mix of those willing to cover medications and those unable to afford them [39][42] AI Integration - Omada is leveraging AI technologies to enhance member engagement and operational efficiency, with tools like Omada Spark and Meal Map [49][50] - AI is seen as a means to improve care team efficiency and increase revenue per user (ARPU) while maintaining quality of care [53][54] Strategic Partnerships - Collaboration with telehealth partners for medication prescriptions to streamline operations and enhance member experience [32][36] - Positive feedback from channel partners like CVS, indicating a gradual build-up of trust and client acquisition [47] Future Outlook - Omada aims to maximize the benefits of new medications and technologies through integrated care solutions, positioning itself as a leader in the health tech space [57] - The company is focused on product innovation and expanding its service offerings to meet diverse employer needs [57][58]

Financial Data and Key Metrics Changes - Total members increased by 53% year over year to 831,000, with revenue growing by 49% year over year to $68 million [4][22] - GAAP gross margin reached 66%, while non-GAAP gross margin was at 68%, both showing significant improvement from the previous year [4][23] - The net loss was reduced to $3 million compared to $9 million in Q3 2024, marking a notable improvement in financial performance [4][24] - For the first time, the company achieved a positive adjusted EBITDA of $2 million, compared to a loss of $5 million in Q3 2024 [4][24] Business Line Data and Key Metrics Changes - The GLP-1 CareTrack program has been a significant driver of growth, reflecting strong demand and multi-condition adoption [11][22] - The company reported that 75% of new customers opted for multiple Omada programs, indicating the appeal of its integrated multi-condition platform [12] Market Data and Key Metrics Changes - The company has seen healthy activity in the current selling season, with early sales traction through a large new channel partner, representing an estimated 180,000 individuals [11] - The demand for GLP-1 offerings has been a key factor in the company's growth, with significant interest from employers and health plans [6][22] Company Strategy and Development Direction - The company plans to invest in GLP-1 offerings and AI technologies, aiming to enhance its solutions and widen its competitive moat [9][25] - The strategic focus is on delivering integrated care that combines clinical services with behavioral support, addressing the complexities of medication management [6][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the potential for growth in 2026 and beyond, driven by innovations in GLP-1 therapies and AI integration [9][10] - The company aims to achieve sustained profitability while continuing to invest in key areas that can enhance its service offerings [25] Other Important Information - The company published its 30th peer-reviewed manuscript, demonstrating the effectiveness of its programs in reducing medical costs and improving health outcomes [18][19] - The company ended Q3 with cash and cash equivalents of $199 million, down from $223 million in Q2 2025, primarily due to debt repayment [25] Q&A Session Summary Question: Can you discuss the new GLP-1 prescribing initiative? - Management highlighted that the new prescribing capability will be integrated within the Omada Care program, allowing members to fulfill prescriptions at their chosen pharmacy [30][31] Question: What investments are needed to launch this new offering? - Management indicated that investments will be required across engineering, product, sales, and marketing to support the new prescribing functionality [39] Question: How is the selling season progressing? - Management noted that they are seeing strong multi-product penetration and healthy activity in the selling season, with double-digit volume deal growth year over year [40] Question: How does GLP-1 drive growth in the overall portfolio? - Management stated that while GLP-1 CareTrack contributes to growth, the majority of new members still come from non-GLP-1 offerings, reflecting a successful multi-product sales strategy [76]

Core Insights - Omada Health has appointed Dr. Thomas Tsang as Chief Medical Officer to lead its clinical organization and enhance clinical quality and innovation [1][2][4] Company Overview - Omada Health is a virtual-first healthcare provider focused on chronic conditions such as diabetes, hypertension, and musculoskeletal issues, serving over 2,000 customers including health plans and Fortune 500 companies [5][6] - The company has implemented clinically-validated behavior change protocols and has over a decade of experience with 30 peer-reviewed publications demonstrating its clinical and economic results [5] Leadership and Experience - Dr. Tsang has a strong background in virtual care delivery, having previously served as founding CEO of Valera Health, where he raised over $75 million and scaled the company to over 500 employees [2][3] - His experience includes roles as Chief Medical Officer at Merck Healthcare Services and as a Medical Director under the Obama Administration, contributing to national health policy and electronic health records [3] Strategic Initiatives - Omada is expanding its GLP-1 Care Track, which has served over 100,000 members since its launch, and enhancing its AI capabilities with tools like OmadaSpark and Meal Map for personalized nutrition [4] - The company aims to combine innovative technology with human-led care to improve member engagement and health outcomes [4]

Core Insights - Omada Health has launched Meal Map, a new AI-powered tool designed to enhance meal tracking and member engagement in its cardiometabolic programs, focusing on nutrient quality rather than restrictive dieting [1][2][3] Company Overview - Omada Health is a virtual-first healthcare provider that implements clinically-validated behavior change protocols for individuals with chronic conditions such as diabetes and hypertension, serving over 2,000 customers including health plans and employers [5][6] Product Features - Meal Map provides instant feedback on the nutrient composition of meals and weekly progress reports on nutritional quality and water intake, aiming to improve members' relationship with food by promoting a nutrient-dense approach [2][3][4] - The tool is integrated with OmadaSpark, an AI-powered nutrition education tool that offers dietitian-vetted recipes based on tracked meals [3] Market Positioning - The introduction of Meal Map addresses a gap in the market for tools that prioritize nutritional value over calorie counting, aligning with the growing demand for sustainable health approaches beyond fad diets [2][4]